Michael Degrandpre

About Michael Degrandpre

I work at the intersection of two things that don\'t always speak the same language: the pharmaceutical industry and the patient community. My career has been built on closing that gap — listening carefully to patients, advocacy leaders, and communities navigating serious, often rare conditions, and turning what I hear into meaningful action.Over 15+ years spanning biopharma, nonprofit, and agency environments, I\'ve built deep expertise across the PA/PA ecosystem: PAG partnerships, disease awareness and education campaigns, drug pricing and access narratives, Patient Focused Drug Development, and federal policy advocacy. Equally fluent in industry strategy and the lived reality of patients — and I believe that combination is what turns good intentions into real impact.

Experience

1. Associate Director, U s Neurology Communications

   Sanofi

   Feb 2025 — Present · Cambridge, MA, US

   Communications lead for tolebrutinib, a first-in-class BTK inhibitor in MS, and the broader U.S. Neurology portfolio. Worked as a regular strategic partner with the Public Affairs & Patient Advocacy team — contributing to engagement planning, stakeholder messaging, and patient education for the MS community.Drove disease state education (DSE) as a core strategic priority — developing content, campaigns, and tools that helped people living with MS understand their condition, navigate their care, and engage meaningfully with the science behind emerging treatments. Managed the budget, led the Communications agency relationship, and served on the U.S. Neurology Leadership Team.

Education

• Saint Michael's College

  Bachelor of Arts - BA, Communication, Journalism, and Related Programs

  2003 — 2007